Amazon cover image
Image from Amazon.com

Multiple sclerosis therapeutics / edited by Richard A . Rudrick, Donald E. Goodkin

Contributor(s): Publication details: San Francisco : Martin Dunitz, c1999Description: xv. 574 p. : ill. ; 25 cmISBN:
  • 9781853178122
  • 1853178128
Subject(s): DDC classification:
  • WL 360 M961 1999 M961 1999
Contents:
Contents 1. Aspects Of Multiple Sclerosis that Relate to Clinical Trial Design and Treatment 2. Clinical Trial Methodology 3. Measures of Impairment and Disability 4. Measures of Neuropsychological Function 5. Measures of Quality of Life 6. Measures of Gadolinium Enhancement 7. Measures of Magnetization Transfer 8. Measures of T1 and T2 Relaxation 9. Measures of Brain and Spinal Cord Atrophy 10. Measures for Quantification of Axonal Damage in vivo Based on MRS Imaging 11. Body Fluid Markers for Disease Course and Activity 12. The Use of Cost Analyses to Improve Our Understanding of the Therapeutic Trade-offs for Multiple Sclerosis 13. The Application of Ethical Principles to Clinical Trials 14. The Process of Drug Approval and Labeling in the USA 15. The Process of Drug Approval and Labeling in Canada 16. The Process of Drug Approval in the European Union 17. Sponsors, Monitoring Committees, The Investigator's Perspective 18. Standardized Reporting of Randomized Controlled Multiple Sclerosis Clinical Trials 19. The Negative Clinical Trial: Failure or Opportunity 20. Emerging Concepts of Pathogenesis: Relationship to Multiple Sclerosis Therapies 21. Interferons 22. Glatiramer Acetate 23. Cladribine 24. Intravenous Immunoglobulin 25. Therapeutic Plasma Exchange 26. Mitoxantrone 27. Methylprednisolone 28. Hematopoietic Stem Cell Transplantation 29. Emerging Disease-modifying Therapies 30. Combination Therapies 31. To Treat or Not to Treat 32. Treatment for Patients with Relapsing-remitting Multiple Sclerosis 33. Treatment for Patients With Secondary Progressive Multiple Sclerosis 34. Treatment for Patients With Primary Progressive and Progressive-relapsing Multiple Sclerosis 35. Treatment of Fatigue in Multiple Sclerosis 36. Treatment of Spasticity 37. Treatment of Bladder and Sexual Dysfunction 38. Treatment of Mood and Affective Disorders 39. Treatment of Chronic Pain 40. Treatment of Paroxysmal Symptoms 41. Treatment of Tremor
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Call number Copy number Status Date due Barcode
Book Open Access Book Open Access Health Sciences Library WL 360 M961 1999 (Browse shelf(Opens below)) 1 Available MBAL22010356

Includes Bibliographical references and Index

Contents
1. Aspects Of Multiple Sclerosis that Relate to Clinical Trial Design and Treatment
2. Clinical Trial Methodology
3. Measures of Impairment and Disability
4. Measures of Neuropsychological Function
5. Measures of Quality of Life
6. Measures of Gadolinium Enhancement
7. Measures of Magnetization Transfer
8. Measures of T1 and T2 Relaxation
9. Measures of Brain and Spinal Cord Atrophy
10. Measures for Quantification of Axonal Damage in vivo Based on MRS Imaging
11. Body Fluid Markers for Disease Course and Activity
12. The Use of Cost Analyses to Improve Our Understanding of the Therapeutic Trade-offs for Multiple Sclerosis
13. The Application of Ethical Principles to Clinical Trials
14. The Process of Drug Approval and Labeling in the USA
15. The Process of Drug Approval and Labeling in Canada
16. The Process of Drug Approval in the European Union
17. Sponsors, Monitoring Committees, The Investigator's Perspective
18. Standardized Reporting of Randomized Controlled Multiple Sclerosis Clinical Trials
19. The Negative Clinical Trial: Failure or Opportunity
20. Emerging Concepts of Pathogenesis: Relationship to Multiple Sclerosis Therapies
21. Interferons
22. Glatiramer Acetate
23. Cladribine
24. Intravenous Immunoglobulin
25. Therapeutic Plasma Exchange
26. Mitoxantrone
27. Methylprednisolone
28. Hematopoietic Stem Cell Transplantation
29. Emerging Disease-modifying Therapies
30. Combination Therapies
31. To Treat or Not to Treat
32. Treatment for Patients with Relapsing-remitting Multiple Sclerosis
33. Treatment for Patients With Secondary Progressive Multiple Sclerosis
34. Treatment for Patients With Primary Progressive and Progressive-relapsing Multiple Sclerosis
35. Treatment of Fatigue in Multiple Sclerosis
36. Treatment of Spasticity
37. Treatment of Bladder and Sexual Dysfunction
38. Treatment of Mood and Affective Disorders
39. Treatment of Chronic Pain
40. Treatment of Paroxysmal Symptoms
41. Treatment of Tremor

There are no comments on this title.

to post a comment.